Drugs & Targets FDA issues guidance to enhance diversity in clinical trials, encourage inclusivity in medical product development November 13, 2020Vol.46 No.43
Drugs & Targets European Commission approves Opdivo + Yervoy with two cycles of chemotherapy for first-line treatment of metastatic NSCLC November 13, 2020Vol.46 No.43
Drugs & TargetsFree Lynparza approved in the EU as first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer November 06, 2020Vol.46 No.42
Drugs & TargetsFree Kymriah receives approval for commercial manufacturing in Japan November 06, 2020Vol.46 No.42
Drugs & Targets FoundationOne CDx test receives FDA approval as companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi October 30, 2020Vol.46 No.41
Drugs & Targets FDA approves cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in NSCLC October 30, 2020Vol.46 No.41
Drugs & Targets CPI-613 receives FDA orphan drug designation for soft tissue sarcoma October 30, 2020Vol.46 No.41
Drugs & Targets EQRx licenses two immune checkpoint inhibitors from CStone Pharmaceuticals. October 30, 2020Vol.46 No.41
